Table 5.

Multivariate analyses of metastasis‐free survival, locoregional control, and overall survival by body composition

	MFS		LRC		OS
Covariate	HR (95% CI)	P value	HR (95% CI)	P value	HR (95% CI)	P value
T‐Stage (T4/3 vs. T2/1)	1.804 (1.247–2.608)	0.002	1.172 (0.885–1.552)	0.268	1.719 (1.346–2.195)	<0.001
N‐Stage (N3/2 vs. N1/0)	2.913 (1.978–4.290)	<0.001	1.750 (1.321–2.318)	<0.001	1.938 (1.526–2.461)	<0.001
Lesion (others vs. NPC)	1.145 (0.779–1.683)	0.055	1.441 (1.061–1.957)	<0.001	1.854 (1.405–2.447)	<0.001
Sex (male vs. female)	1.707 (0.894–3.258)	0.105	1.092 (0.659–1.808)	0.733	1.150 (0.749–1.768)	0.523
Smoking (yes vs. no)	0.990 (0.596–1.646)	0.970	1.669 (1.072–2.600)	0.023	1.266 (0.878–1.823)	0.206
Betel quid (yes vs. no)	0.996 (0.654–1.516)	0.984	1.103 (0.797–1.527)	0.555	1.206 (0.913–1.593)	0.188
Alcohol (yes vs. no)	1.106 (0.749–1.634)	0.612	1.376 (1.009–1.877)	0.044	1.271 (0.983–1.642)	0.067
Age (years)a					1.031 (1.019–1.043)	<0.001
Treatment daysa					1.026 (1.004–1.049)	0.021
SAT index (high vs. low)	0.650 (0.459–0.920)	0.015	0.758 (0.577–0.997)	0.047	0.604 (0.478–0.762)	<0.001
SM index (high vs. low)			0.777 (0.588–1.027)	0.077	0.805 (0.639–1.015)	0.066

MFS, metastasis‐free survival; LRC, locoregional control; OS, overall survival; HR, hazard ratio; CI, confidence interval; NPC, nasopharyngeal carcinoma; EQD2 Gy, equivalent dose in 2‐Gy fractions; Gy, gray; PET, positron emission tomography; SAT, subcutaneous fat tissue; SM, skeletal muscle.

^aContinuous variable.